Newsletters - February 2000

Green Tea 30-42 wt%
Oolong Tea 08-20 wt%
Black Tea 03-10 wt%

(*Catechins are mesured as wt% of extract solids)

Initial benefits of oolong tea were first noticed after 1-2 weeks of treatment. Marked to moderate improvement was observed in 74 (63%) of the 118 patients after 1 month. After 6 months of treatment, a good response was still observed in 64 patients (54%). The authors attribute oolong tea’s beneficial effects in the recalcitrant AD cases to the antiallergic properties of the tea’s polyphenols.

Sources: 1. Atopic Dermatitis (publication of the National Institutes of Health and the National Institutes of Arthritis and Musculoskeletal and Skin Diseases. http://www.nih.gov/niams/healthinfo/dermatitis/atophandout_breaks.html. 2. Uehara, M., Sugiura, H., and Sakurai, K. (2001) Arch Dermatol. 137, 42-43. 3. Graham, H.N. (1992) Prev. Med. 21, 334-350.

Sabinsa Corporation supplies two grades of green tea, one standardized for a minimum of 40% catechins and the other for a minimum of 75%. Green Tea CG (cosmetic grade) is also available. It is standardized for a minimum of 75% catechins. Please contact Sabinsa for information about our green tea products and the other products of our nutritional, cosmeceutical, and functional food lines.

    VISIT US

  • Sabinsa Canada Inc.
    6800 Kitimat Road, Unit 28,
    Mississauga, ON L5N 5M1
    Canada

  • +1 905-286-6616
  • +1 437-988-1663
  • info@sabinsa.ca

CERTIFICATES

Certificate Logos Certificate Logos
Certificate Logos Certificate Logos

CONTACT US

Disclaimer

Please note that this website and information provided herein is not for final consumers of a finished food, beverage, dietary supplement product or cosmetic product, as the information contained herein does not refer to finished products for consumers.

The information provided on the website is intended only for producers of finished food, beverage, dietary supplement and cosmetic product.

The statements related to ingredients on the website, have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

The website and information herein are available in various countries across the world, and hence statements or product information including its classification may not be applicable in your country.

Information and statements provided on the website, shall not be construed as license to practice, or recommendations to infringe, any patents or other intellectual property rights of Sabinsa and others.

By browsing further, You understand the above terms.